David CarlucciChief Operating Officer

Slide 2:David Carlucci Chief Operating Officer

Slide 3:Safe Harbor Certain statements we make today are forward-looking within the meaning of US federal securities laws. These statements include, certain projections regarding the trends in our business, future events and future financial performance. We would like to caution you that these statements are just predictions, and the actual event or results may differ. They can be affected by inaccurate assumptions or by known or unknown risks or uncertainties. Consequently, no forward-looking statement can be guaranteed. We call your attention to our first quarter 2004 earnings release and our 2003 annual report on Form 10-K, which set forth important factors that could cause actual results to differ materially from those contained in any such forward-looking statements. All forward-looking statements represent our views only as of the date they are made and the Company undertakes no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise.

Slide 5:IMS Snapshot NYSE: RX Founded in 1954: �Intercontinental Medical Statistics� $1.38 billion in revenues 13% growth in 2003 Over 60% revenue outside the U.S. $100+ M in Consulting and Services 6000 employees in 100 countries 73% outside the US Clients include every pharmaceutical & biotech company Track over 1 million brands, daily www.imshealth.com Here is a brief overview of IMS. We won�t be covering our illustrious history today, but I encourage you to read about it on our Global Intranet. The annual report is also on the Intranet as well as a corporate brochure that goes into great detail about our business. As you can see, we�ve been around for exactly half a century and are celebrating our 50th anniversary this year. We no longer refer to the long name of the company. The acronym IMS is now such a strong brand in the pharmaceutical industry, that our letters say it all. We are a global company, and not just by location, but in attitude, philosophy and operations. We are very successful � we�ve remained the market leader for all of our 50 years, and we intend to stay that way. Our stock is listed on the New York Stock Exchange as RX, and we closed yesterday at (get number from Global Intranet stock) Our corporate headquarters are in Connecticut in the US. Regional headquarters are located in London, England for Europe, Africa and the Middle East; Tokyo, Japan for Asia Pacific; Pointe Claire, Quebec for Canada, Asia and Latin America; and Plymouth Meeting, Pennsylvania for the US. Here is a brief overview of IMS. We won�t be covering our illustrious history today, but I encourage you to read about it on our Global Intranet. The annual report is also on the Intranet as well as a corporate brochure that goes into great detail about our business. As you can see, we�ve been around for exactly half a century and are celebrating our 50th anniversary this year. We no longer refer to the long name of the company. The acronym IMS is now such a strong brand in the pharmaceutical industry, that our letters say it all. We are a global company, and not just by location, but in attitude, philosophy and operations. We are very successful � we�ve remained the market leader for all of our 50 years, and we intend to stay that way. Our stock is listed on the New York Stock Exchange as RX, and we closed yesterday at (get number from Global Intranet stock) Our corporate headquarters are in Connecticut in the US. Regional headquarters are located in London, England for Europe, Africa and the Middle East; Tokyo, Japan for Asia Pacific; Pointe Claire, Quebec for Canada, Asia and Latin America; and Plymouth Meeting, Pennsylvania for the US.

Slide 6:Profound Franchise

Slide 7:Data Suppliers

Slide 8:IMS Transformation Will build from left to right � new one comingWill build from left to right � new one coming

Slide 9:Market Opportunity and IMS Share � let me now show you their market opportunity $4-5Billion in total Shared with you last year, and since has been validated This is current size and could be considered conservative since -- does not consider expansion -- does not consider internal spend Our lead segments are PO and SFE where we have around 50% of the market. � and we want more Our growth segments are L and BM, which are real �market entry� for us. This is where accessing new audiences and new budgets will pay off. And we are building out our offerings in the last two. T: This set of opportunities leads to our LT Growth Model � let me now show you their market opportunity $4-5Billion in total Shared with you last year, and since has been validated This is current size and could be considered conservative since -- does not consider expansion -- does not consider internal spend Our lead segments are PO and SFE where we have around 50% of the market. � and we want more Our growth segments are L and BM, which are real �market entry� for us. This is where accessing new audiences and new budgets will pay off. And we are building out our offerings in the last two. T: This set of opportunities leads to our LT Growth Model

Slide 10:Continuum of Capabilities Without exaggeration, we can do anything for anyone! And that�s the point. From Data to Recommendation, we are there. (Walk through the definitions) Client needs aren�t stable. The same client may want a data extract on Monday for their enterprise-wide warehouse�and on Friday, an ingoing reimbursement strategy and ongoing performance tracking for a significant new product. And we can meet both those needs. T: Let me give you a better sense of what we have and what we can do. Without exaggeration, we can do anything for anyone! And that�s the point. From Data to Recommendation, we are there. (Walk through the definitions) Client needs aren�t stable. The same client may want a data extract on Monday for their enterprise-wide warehouse�and on Friday, an ingoing reimbursement strategy and ongoing performance tracking for a significant new product. And we can meet both those needs. T: Let me give you a better sense of what we have and what we can do.

Slide 12:Sources of CD Revenue Growth On the left, our recently-achieved growth On the right, our LT model The good thing about SFE is they need us whether they are shrinking or growing their salesforces! We are confident in that number PO looks modest, but it is a mature segment. We will look to expand the processes served there, say into late development The last two look like BAU, but they are not. They actually represent a VERY stiff challenge, since they are entry growth rates from a small base. Sustaining these double-digit rates will be an excellent achievement We know what our customers need. T: Let�s look at opportunity another way On the left, our recently-achieved growth On the right, our LT model The good thing about SFE is they need us whether they are shrinking or growing their salesforces! We are confident in that number PO looks modest, but it is a mature segment. We will look to expand the processes served there, say into late development The last two look like BAU, but they are not. They actually represent a VERY stiff challenge, since they are entry growth rates from a small base. Sustaining these double-digit rates will be an excellent achievement We know what our customers need. T: Let�s look at opportunity another way

Slide 13:Factors We Model into our Business

Slide 15:3rd Party Positioning vs. Other Franchises

Slide 16:Investment Features